Proxy Deadline Thursday September 26, 2024

Rhea-AI Summary

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) has issued a reminder for shareholders to vote ahead of the company's annual and special shareholders meeting scheduled for Monday, September 30, 2024. Currently, less than half of Titan's common shares have been voted in advance of the meeting. The company urges shareholders to VOTE TODAY.

The Management Information Circular and related materials for the meeting are available on Titan's website and under the company's SEDAR+ profile. A recording of the September 19, 2024 Shareholders Q&A session is also accessible on Titan's website. Shareholders requiring assistance with voting or having questions about the meeting can contact Shorecrest Group via phone or email.

TORONTO, Ontario, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) released a reminder for shareholders to vote ahead of Titan’s annual and special shareholders meeting (the “Meeting”) scheduled to be held on Monday, September 30, 2024.

Less than half of the Titan common shares have been voted in advance of the Meeting.

VOTE TODAY.

The Management Information Circular (the “Circular”) and related materials for the Meeting are available on Titan’s website at https://ir.titanmedicalinc.com/news-events/shareholder-meeting and under Titan’s SEDAR+ profile at www.sedarplus.ca.

For a recording of the September 19, 2024 Shareholders Q&A session visit Titan’s website at https://ir.titanmedicalinc.com/news-events/ir-calendar/detail/9950/qa-session-with-shareholders.

Shareholder Questions and Assistance.

Shareholders who have any questions about the Meeting, or require assistance with voting, may contact Shorecrest Group by telephone at 1-888-637-5789 or +1-647-931-7454 (Bankers & Brokers/collect calls outside North America) or by email at contact@shorecrestgroup.com.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical

Conavi Medical Inc. is a privately-owned company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit http://www.conavi.com/.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: regarding the Amalgamation, including the anticipated timing of the Meeting, and other statements that are not historical facts.

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration; the receipt of required approvals from the TSXV and Titan’s shareholders in connection with the Transaction or change of listing or as to the success of Conavi’s Concurrent Financing (or the terms upon which such financing may be available if at all)and other factors listed in the “Risk Factors” section of Titan’s Annual Information Form for the fiscal year ended December 31, 2023 (which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contacts

Titan Medical Inc.                                                
Chien Huang                                                        
Chief Financial Officer                                        
investors@titanmedicalinc.com

###

FAQ

When is the deadline for Titan Medical Inc. (TMDIF) shareholders to vote for the annual meeting?

The deadline for Titan Medical Inc. (TMDIF) shareholders to vote for the annual and special shareholders meeting is Thursday, September 26, 2024.

What percentage of Titan Medical Inc. (TMDIF) shares have been voted ahead of the September 30, 2024 meeting?

Less than half of Titan Medical Inc. (TMDIF) common shares have been voted in advance of the September 30, 2024 annual and special shareholders meeting.

Where can shareholders find the Management Information Circular for Titan Medical Inc.'s (TMDIF) 2024 annual meeting?

Shareholders can find the Management Information Circular for Titan Medical Inc.'s (TMDIF) 2024 annual meeting on the company's website at https://ir.titanmedicalinc.com/news-events/shareholder-meeting and under Titan's SEDAR+ profile at www.sedarplus.ca.

How can shareholders get assistance with voting for Titan Medical Inc.'s (TMDIF) 2024 annual meeting?

Shareholders can get assistance with voting for Titan Medical Inc.'s (TMDIF) 2024 annual meeting by contacting Shorecrest Group at 1-888-637-5789 or +1-647-931-7454, or by email at contact@shorecrestgroup.com.